NO309935B1 - Nye bis-pyrido[4,3-b]karbazolforbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder disse - Google Patents
Nye bis-pyrido[4,3-b]karbazolforbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder disse Download PDFInfo
- Publication number
- NO309935B1 NO309935B1 NO983602A NO983602A NO309935B1 NO 309935 B1 NO309935 B1 NO 309935B1 NO 983602 A NO983602 A NO 983602A NO 983602 A NO983602 A NO 983602A NO 309935 B1 NO309935 B1 NO 309935B1
- Authority
- NO
- Norway
- Prior art keywords
- pyrido
- carbon atoms
- compounds
- compound
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 4
- 150000002430 hydrocarbons Chemical group 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 3
- 230000003287 optical effect Effects 0.000 claims abstract description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 25
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 125000004556 carbazol-9-yl group Chemical group C1=CC=CC=2C3=CC=CC=C3N(C12)* 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 7
- 229960000250 adipic acid Drugs 0.000 claims description 5
- 235000011037 adipic acid Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 8
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Olivacine Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 hexafluorophosphate Chemical compound 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- XJMMNTGIMDZPMU-UHFFFAOYSA-N 3-methylglutaric acid Chemical compound OC(=O)CC(C)CC(O)=O XJMMNTGIMDZPMU-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
- ZNMDSQBHOLGTPA-UHFFFAOYSA-N 2,2,5,5-tetramethylhexanedioic acid Chemical compound OC(=O)C(C)(C)CCC(C)(C)C(O)=O ZNMDSQBHOLGTPA-UHFFFAOYSA-N 0.000 description 1
- HUOXNKQMXIKHRJ-UHFFFAOYSA-N 2-[1-[2-[1-[2-(dimethylamino)ethylcarbamoyl]-5,6-dimethylpyrido[4,3-b]carbazol-9-yl]oxy-2-oxoethyl]cyclohexyl]acetic acid Chemical compound C1=C2C=3C=C4C(C(=O)NCCN(C)C)=NC=CC4=C(C)C=3N(C)C2=CC=C1OC(=O)CC1(CC(O)=O)CCCCC1 HUOXNKQMXIKHRJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9710066A FR2767132B1 (fr) | 1997-08-06 | 1997-08-06 | Nouveaux composes de bis pyrido [4,3-b] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
Publication Number | Publication Date |
---|---|
NO983602D0 NO983602D0 (no) | 1998-08-05 |
NO983602L NO983602L (no) | 1999-02-08 |
NO309935B1 true NO309935B1 (no) | 2001-04-23 |
Family
ID=9510082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO983602A NO309935B1 (no) | 1997-08-06 | 1998-08-05 | Nye bis-pyrido[4,3-b]karbazolforbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder disse |
Country Status (19)
Country | Link |
---|---|
US (1) | US5958938A (xx) |
EP (1) | EP0895995B1 (xx) |
JP (1) | JPH11100379A (xx) |
CN (1) | CN1087018C (xx) |
AT (1) | ATE218574T1 (xx) |
AU (1) | AU737770B2 (xx) |
BR (1) | BR9802850A (xx) |
CA (1) | CA2244508C (xx) |
DE (1) | DE69805709T2 (xx) |
DK (1) | DK0895995T3 (xx) |
ES (1) | ES2178128T3 (xx) |
FR (1) | FR2767132B1 (xx) |
HK (1) | HK1017686A1 (xx) |
HU (1) | HUP9801822A3 (xx) |
NO (1) | NO309935B1 (xx) |
NZ (1) | NZ331267A (xx) |
PL (1) | PL327873A1 (xx) |
PT (1) | PT895995E (xx) |
ZA (1) | ZA987076B (xx) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584679B (zh) * | 2011-01-13 | 2015-06-17 | 中国科学院上海药物研究所 | 一类苯并咔唑酰胺类化合物、其制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2696465B1 (fr) * | 1992-10-02 | 1994-12-23 | Adir | Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
-
1997
- 1997-08-06 FR FR9710066A patent/FR2767132B1/fr not_active Expired - Fee Related
-
1998
- 1998-07-22 US US09/120,899 patent/US5958938A/en not_active Expired - Fee Related
- 1998-08-03 JP JP10218957A patent/JPH11100379A/ja active Pending
- 1998-08-04 EP EP98401979A patent/EP0895995B1/fr not_active Expired - Lifetime
- 1998-08-04 PT PT98401979T patent/PT895995E/pt unknown
- 1998-08-04 ES ES98401979T patent/ES2178128T3/es not_active Expired - Lifetime
- 1998-08-04 DK DK98401979T patent/DK0895995T3/da active
- 1998-08-04 AT AT98401979T patent/ATE218574T1/de not_active IP Right Cessation
- 1998-08-04 DE DE69805709T patent/DE69805709T2/de not_active Expired - Fee Related
- 1998-08-05 CN CN98118007A patent/CN1087018C/zh not_active Expired - Fee Related
- 1998-08-05 NO NO983602A patent/NO309935B1/no unknown
- 1998-08-05 BR BR9802850-2A patent/BR9802850A/pt not_active IP Right Cessation
- 1998-08-05 NZ NZ331267A patent/NZ331267A/xx unknown
- 1998-08-05 CA CA002244508A patent/CA2244508C/fr not_active Expired - Fee Related
- 1998-08-06 HU HU9801822A patent/HUP9801822A3/hu unknown
- 1998-08-06 AU AU78836/98A patent/AU737770B2/en not_active Ceased
- 1998-08-06 PL PL98327873A patent/PL327873A1/xx not_active IP Right Cessation
- 1998-08-06 ZA ZA987076A patent/ZA987076B/xx unknown
-
1999
- 1999-07-05 HK HK99102827A patent/HK1017686A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU7883698A (en) | 1999-02-18 |
PT895995E (pt) | 2002-09-30 |
US5958938A (en) | 1999-09-28 |
HUP9801822A2 (hu) | 1999-04-28 |
HUP9801822A3 (en) | 2000-01-28 |
CN1087018C (zh) | 2002-07-03 |
FR2767132B1 (fr) | 1999-09-10 |
CN1207393A (zh) | 1999-02-10 |
DE69805709T2 (de) | 2003-01-30 |
AU737770B2 (en) | 2001-08-30 |
FR2767132A1 (fr) | 1999-02-12 |
JPH11100379A (ja) | 1999-04-13 |
ES2178128T3 (es) | 2002-12-16 |
EP0895995B1 (fr) | 2002-06-05 |
PL327873A1 (en) | 1999-02-15 |
EP0895995A1 (fr) | 1999-02-10 |
CA2244508C (fr) | 2003-04-01 |
ZA987076B (en) | 1999-02-08 |
CA2244508A1 (fr) | 1999-02-06 |
NZ331267A (en) | 1999-07-29 |
HU9801822D0 (en) | 1998-10-28 |
HK1017686A1 (en) | 1999-11-26 |
DE69805709D1 (de) | 2002-07-11 |
NO983602D0 (no) | 1998-08-05 |
BR9802850A (pt) | 2000-02-08 |
NO983602L (no) | 1999-02-08 |
ATE218574T1 (de) | 2002-06-15 |
DK0895995T3 (da) | 2002-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cao et al. | Synthesis, acute toxicities, and antitumor effects of novel 9-substituted β-carboline derivatives | |
AU2014291161B2 (en) | Antitumor drug for intermittent administration of FGFR inhibitor | |
ES2277568B1 (es) | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
JP5892620B2 (ja) | ピラゾール誘導体 | |
CA3002884A1 (en) | Protein kinase inhibitors, preparation method and medical use thereof | |
KR20190098266A (ko) | 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용 | |
CA2208639C (en) | Camptothecin derivatives and its manufacturing method | |
CN111848718A (zh) | 雷公藤红素含氮五元杂环类衍生物及其制备方法与用途 | |
CN105085383B (zh) | 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途 | |
NO309935B1 (no) | Nye bis-pyrido[4,3-b]karbazolforbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder disse | |
EP0687673A1 (en) | Oxazole derivatives as antitumoral agents | |
RU2169149C2 (ru) | Соединения со структурой камптотецина, способы их получения, фармацевтические композиции | |
CN108440550A (zh) | 一种异苯并二氢吡喃并吲哚衍生物及其制备方法 | |
CN110156816B (zh) | 一种四氢吡唑并哌嗪类化合物及其制备方法及应用 | |
AU736292B2 (en) | New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them | |
KR920002143B1 (ko) | 5-치환 우리딘 유도체 및 그의 제조 중간체 | |
CN115197206B (zh) | 吲哚3-位取代的四氢-γ-咔啉化合物、其药物组合物及用途 | |
CN116120291B (zh) | 吲唑类化合物及其制备方法和应用 | |
EP0433678A1 (en) | Alkoxymethylidene epipodophyllotoxin glucosides | |
EP0516157A1 (en) | Preparation of 6-0-alkylelsamicin A derivatives | |
Zhang et al. | Design, synthesis and biological evaluation of novel spin-labeled derivatives of podophyllotoxin | |
US5919791A (en) | Ellipticine compounds | |
EP0456514A1 (en) | 2-Fluoroneplanocin A and its production | |
CN101861309A (zh) | Salarin和tulearin以及它们的组合物和应用 | |
SA08290382B1 (ar) | مشتقات 1- سيانوسيكو بروبيل متضمنة نظام حلقة ثلاثي حلقي وإستخدامها في العلاج |